Preventing CRS and ICANS Across Sites of Care

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Issam S. Hamadeh, PharmD, BCPS, BCOP

Key Takeaways

Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Patient-specific factors, including comorbidities and previous treatment responses, are crucial in determining the appropriate dosing schedule and formulary inclusion.

Panelists discuss understanding institutional protocols for managing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) prophylaxis in bispecific antibody therapy, along with criteria for safely selecting patients for outpatient step-up dosing.

EP: 1.Current Landscape of Bispecific Therapies for RRMM

EP: 2.Operationalizing Bispecific Therapy and the Impact of CAR T Advancements on Sequencing

EP: 3.Best Practices for Standardizing Step-Up Dosing

EP: 4.Dosing Frequency and Formulary Decisions for Bispecific Antibodies

EP: 5.Resources and Education for Operationalizing Bispecifics

EP: 6.Safety Profiles of Bispecific Antibodies for RRMM

Now Viewing

EP: 7.Preventing CRS and ICANS Across Sites of Care

EP: 8.Managing CRS and ICANS: Approaches and Protocols

EP: 9.Infection Prevention and Leveraging EHR for Bispecific Therapy Management

EP: 10.Navigating REMS Requirements and Educating Other Stakeholders on Bispecific Therapies

EP: 11.Administering Bispecifics in the Community vs Academic Centers

EP: 12.Improving Transitions of Care for Patients Receiving Bispecific Therapies and Final Recommendations

Video content above is prompted by the following

What supportive care measures are utilized prophylactically at your institution for patients receiving bispecific antibodies to prevent CRS and ICANS?
What criteria would be important to consider when determining patient eligibility for outpatient administration of step-up dosing for bispecific antibodies, considering the higher risk of toxicities during this phase?

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!